NCATS Drug Repurposing

At the National Center for Advancing. Translational Sciences (NCATS), drug repurposing is a key strategy for bringing more treatments for all people more ...

NCATS Funds New Drug Repurposing Projects, Seeks Additional ...

NCATS recently awarded funding for three new projects to repurpose compounds that have already undergone significant research and development by industry.

Our Impact on Drug Discovery and Development

Drug Repurposing Reveals HIV Drug Shows Promise for Muscle Disorder ... NCATS-supported researchers show that an existing antiviral drug used against HIV ...

New Therapeutic Uses | National Center for Advancing Translational ...

In response, NCATS created the Drug Repurposing Toolbox to provide easy access to guidance, relevant publications, information about repurposing conferences and ...

NCATS Pharmaceutical Collection

... drug repurposing data and experiments for all approved drugs. To ... compounds from the NCATS Pharmaceutical Collection, for their ...

Exploring NCATS in-house biomedical data for evidence-based ...

Drug repurposing is a strategy for identifying new uses of approved or investigational drugs that are outside the scope of the original medical indication.

NCATS Inxight Drugs: a comprehensive and curated portal for ...

... treatment of COVID-19 reinforced the importance of drug repurposing in translational research. Understanding the regulatory status of these ...

Large Clinical Trial to Study Repurposed Drugs to Treat COVID-19 ...

D., NCATS acting director. “By leveraging drug repurposing and existing national clinical trial networks, ACTIV-6 aims to speed the delivery ...

The NCATS Pharmaceutical Collection: a 10-year update

... National Center for Advancing Translational Sciences (NCATS) Pharmaceutical ... Drug repurposing or repositioning, defined as the application of an existing drug ...

NCATS launches drug repurposing program - ResearchGate

A new project by the National Institutes of Health aims to persuade drug companies to open up their troves of abandoned drugs to academics, who would look for ...

NCATS Funding Available to Repurpose Existing Drugs

NCATS Funding Available to Repurpose Existing Drugs. Crystal McKnight examines a compound source plate. ... NCATS has announced funding opportunities to use ...

Therapeutic Repurposing - Google Sites

This was born out of the off-patent repurposing workshop held in December 2019 but includes information for drug repurposing in general. *This ...

NCATS launches drug repurposing program | Nature Biotechnology

NCATS launches drug repurposing program ... A newly launched initiative from the US National Institutes of Health (NIH) National Center for ...

NIH NCATS case study: using accelerated screening research for ...

Drug Repurposing can be an effective way to identify novel treatments for diseases, especially when time is of the essence. Research scientists at National ...

CURE Drug Repurposing Collaboratory - Critical Path Institute

... drug repurposing and inform future clinical trials for diseases of high unmet medical need. ... * The CURE ID mobile app is an FDA-NCATS collaboration to build an ...

OpenData Portal | National Center for Advancing Translational ...

... drugs in new ways. This approach is called drug repurposing and can cut the time it takes to develop U.S. Food and Drug Administration–approved ...

Exploring NCATS In-House Biomedical Data for Evidence-based ...

Drug repurposing is a strategy for identifying new uses of approved or investigational drugs that are outside the scope of the original medical ...

Old drugs, new uses: advances in drug repurposing and the federal ...

Old drugs, new uses: advances in drug repurposing and the federal outlook. Pharmaceutical. 14 March 2023. fda-blog-700.

The NIH Promotes Drug Repurposing and Rescue NewsBriefs - jstor

Eli Lily and Company has an- nounced that it will systematically screen the NCATS Pharmaceutical Collection using its Phenotypic Drug Discovery. Panel, which ...

NCATS Awards $12.7M for Nine Drug Repurposing Projects

Janssen, Sanofi, Pfizer, Lilly, and AstraZeneca are five of eight pharma giants contributing compounds to the pilot program. The others were ...